華東醫藥(000963.SZ)已捐贈價值600多萬元百令膠囊藥品 用於提高醫護人員身體免疫力抵禦新型冠狀病毒肺炎感染
格隆匯2月3日丨華東醫藥(000963.SZ)公佈，作為浙江省和杭州市的應急藥械儲備單位，公司始終高度關注新型冠狀病毒肺炎疫情的進展，並積極投身疫情防控工作，在保持自身企業正常經營和員工防護的同時，切實履行上市公司社會責任。此次疫情發生後，公司及時制定了各項抗擊“新型冠狀病毒感染的肺炎”疫情措施，做好應急值守和儲備調運，確保應急藥械供應與價格穩定，確保重大疫情面前的責任擔當。目前公司生產經營整體穩定。
公司於春節前就根據疫情進展在第一時間成立了疫情應急處置小組，由公司董事長任組長，醫藥商業負責人及採購、供應鏈負責人蔘與，積極對接各級政府主管部門，完善應急供應預案，高效執行浙江省經信廳的調撥令，做好應急藥品及防護物資採購、儲備及調運。已將兩百多萬個各種類型口罩，近十萬件防護服、近萬個測温計發送到疫情防治的重點醫療機構、參與疫情防控的政府部門及社區。同時通過零售藥店、電商平台向廣大市民平價供應防護口罩，努力保障供應，助力疫情防控。
公司主要產品百令膠囊在長期臨牀實踐中證明其具有提高機體免疫力、修復肺腎損傷的功效，已被正式納入浙江省疾控系統防控用品類別清單。截止目前公司已分幾批向浙江全省11個地市的省級醫院及武漢市抗擊疫情一線醫護人員、浙江省赴武漢援助醫療隊及衞健委系統累計捐贈價值600多萬元的百令膠囊藥品，用於提高醫護人員身體免疫力，抵禦新型冠狀病毒肺炎感染。
根據《深圳證券交易所股票上市規則》及《公司章程》等的相關規定，公司此次捐贈藥品事項在董事長審批權限範圍內，無需提交董事會及股東大會審議。
截止目前，本次新型冠狀病毒肺炎疫情對公司生產經營未構成明顯影響，公司的相關藥品捐贈是公司秉承“服務大眾健康”的理念，積極承擔社會責任，踐行“濟世、誠正、執着、務實”的核心價值觀的體現，對公司當期經營及投資者利益不構成重大影響。公司還將繼續關注疫情的發展，積極做好疫情防控工作，確保關鍵藥械的供應保障，為抗擊疫情提供更多力所能及的幫助。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
